A cutting-edge biotech firm based in Manhattan’s Kips Bay neighborhood has secured a $37.5 million partnership with global pharmaceutical giant AstraZeneca to accelerate the development of cancer treatments using artificial intelligence. This agreement marks the third collaboration between the two companies, underscoring their shared commitment to harnessing AI technology for breakthroughs in oncology and inflammatory bowel disease therapies.

Immunai, the Kips Bay startup at the center of the deal, specializes in leveraging AI-driven insights to map the human immune system and identify novel therapeutic targets. The infusion of funds from AstraZeneca will enable Immunai to scale its research capabilities, apply its platform to new cancer indications, and advance promising drug candidates toward clinical trials.

This partnership reflects a broader trend in the New York City biotech scene, where innovative startups and established pharmaceutical firms increasingly collaborate to integrate AI into drug discovery. The city’s rich ecosystem of academic institutions, research hospitals, and venture capital has made neighborhoods like Kips Bay a hotspot for biotech innovation.

For AstraZeneca, the agreement is part of a strategic push to incorporate advanced technologies into their oncology pipeline, aiming to improve patient outcomes with more precise, effective treatments. Both companies plan to continue expanding their joint efforts, signaling a strong future for AI-driven medicine emerging from the heart of NYC’s biotech corridor.

Editorial Transparency. A first draft of this story was produced with AI-assisted writing tools, then reviewed for accuracy and tone by the named editor before publication. More on our process: Editorial Policy.